Although opioids are frequently prescribed for chronic noncancer pain (CNCP) among Veterans Health Administration (VHA) patients, little has been reported on national opioid prescribing patterns in the VHA. Our objective was to better characterize the dosing and duration of opioid therapy for CNCP in the VHA. We analyzed national VHA administrative and pharmacy data for fiscal years 2009 to 2011. For individuals with CNCP diagnoses and any opioid use in the fiscal year, we calculated the distribution of individual mean daily opioid dose, individual total days covered with opioids in a year, and individual total opioid dose in a year. We also investigated the factors associated with being in the top 5% of individuals for total opioid dose in a year, which we term receipt of high-volume opioids. About half of the patients with CNCP received opioids in a given fiscal year. The median daily dose was 21 mg morphine equivalents. Approximately 4.5% had a mean daily dose higher than 120 mg morphine equivalents. The median days covered in a year was 115 to 120 days in these years for those receiving opioids. Fifty-seven percent had at least 90 days covered with opioids per year. Major depression and posttraumatic stress disorder were positively associated with receiving high-volume opioids, but nonopioid substance use disorders were not. Among VHA patients with CNCP, chronic opioid therapy occurs frequently, but for most patients, the average daily dose is modest. Doses and duration of therapy were unchanged from
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Introduction
Chronic noncancer pain (CNCP) is common in Veterans Health Administration (VHA) patients, with over 50% of Veterans Administration (VA) primary care patients reporting chronic pain [25, 26, 35, 38, 42] . Frequently occurring disorders include neck and back pain, arthritis, headache/migraine, and neuropathic pain [19] . Opioids are commonly prescribed for patients with CNCP in both VHA [15, 47] and non-VHA populations [9, 40] . Although this use is supported by guidelines [1, 12, 21, 22] , it is controversial. In particular, there are concerns regarding opioid misuse and abuse, opioid overdose deaths, and the association of opioids with emergency room visits and fractures [3] [4] [5] [6] [7] [8] 10, 13, 16, 23, 29, 30, [32] [33] [34] 40] . Negative outcomes are particularly common among patients receiving high-dose opioids [8, 10, 16, 34] .
Opioid overprescribing is a concern in the VHA, and the VHA has been in the vanguard of developing opioid prescribing guidelines. 
